Recurrence of Shingles in the Older Adult Population by Yang, Leeann
University of North Dakota
UND Scholarly Commons
Nursing Capstones Department of Nursing
4-21-2017
Recurrence of Shingles in the Older Adult
Population
Leeann Yang
Follow this and additional works at: https://commons.und.edu/nurs-capstones
This Independent Study is brought to you for free and open access by the Department of Nursing at UND Scholarly Commons. It has been accepted for
inclusion in Nursing Capstones by an authorized administrator of UND Scholarly Commons. For more information, please contact
zeineb.yousif@library.und.edu.
Recommended Citation
Yang, Leeann, "Recurrence of Shingles in the Older Adult Population" (2017). Nursing Capstones. 31.
https://commons.und.edu/nurs-capstones/31




















University of North Dakota  
 
NURS 997 Independent Study 
 




























 Shingles is an infection of the varicella zoster virus (VZV) and known as herpes zoster 
(HZ) with recurrence. Children who have been vaccinated with varicella seem to have a lower 
rate of HZ than individuals who were exposed to the wild-type VZV (Centers for Disease 
Control, 2016). At this time, 99.5% of the United States population over the age of 40 have been 
infected with the wild-type VZV (CDC, 2016). This may mean that recurrence will be increased 
in our aging population. Currently, the rate is highest amongst the older adults 60 years old and 
older (CDC, 2016). The incidence rate among this population is 10 cases per 1,000/year (CDC, 
2016).  
This report provides an overview of a patient who came into the office with a final 
diagnosis of shingles: at the age of 67 years old, without documentation of varicella vaccination, 
or having realized he had a rash. The clinician's ability to assess and formulate differential 
diagnosis is vital to correct diagnosis, treatment, and education. The importance of piecing 
together the classic signs of HZ along with comparing differential diagnoses, such as herpes 




















 A white male presented to his primary care office with a chief complaint of back pain. He 
also stated he fell two or four days ago on ice. Because of this information, the student conducted 
a musculoskeletal exam to begin. Upon further investigation, he stated the pain to feel like hot 
pins and needles. The pain radiated to his right thigh originating from his right lower back. 
Looking at his chart this patient was 67 years old without a history of shingles vaccination. 
When his shirt was lifted, a classic vesicular rash was visualized on his right lower back, which 
he probably could not see himself.  
 Initially, the diagnosis was missed. Because of this incident, the student became 
interested in the topic of rate of recurrence of shingles.  Investigating the recurrence rate led to 
studies with information on treatment options for patients with reactivation of VZV, known as 
herpes zoster (HZ). Studies that were reviewed showed no known rate of recurrence of VZV. To 
this date, the CDC does not have data on the rate of recurrence of VZV. To conclude, articles 
were examined until the most recent study was found to reveal that recurrence might, in fact, be 


















Patient Case  
 
History 
 The patient made a primary care appointment for chief complaint of back pain. Upon interview, 
the patient reported falling two or four days ago on ice. He denied using any assistive device and 
stated he lived alone. The patient was a sixty-seven year old Caucasian male residing in a private 
home. He denied any recurrent falls since the one mentioned during the interview. He denied 
other injuries such as bruising or history of skin ulcers but stated the pain in his back radiated to 
his right thigh. The patient could not pinpoint how far the pain radiated.   
 For pain control, the patient was taking Tylenol at home 325mg tablets (two at a time a 
couple times a day at most), which he also took for a history of bilateral knee arthritis. Other than 
arthritis the patient stated he has a history of reflux, which he uses Protonix 40mg daily. His pain 
was worse with activity which was reported to go up to a 7-8 on the 0-10 verbal pain scale. 
During the visit, the pain was rated at a 6 out of 10. The patient denied any history of back pain 
such as this, and when asked to characterize pain he stated, "hot pins and needles." The pain 
seemed to be constant but could become worse if laying down on his back or with activity. He 
also stated ice was attempted for relief but made the pain worse.  
Looking over his immunization history there was influenza vaccine 2016 and Tdap in 
2015. The patient did not currently drink alcohol, smoke, or use smokeless tobacco products. The 
patient denied any history of surgeries and family history of back problems. He denied any 
known allergies to medications or food. He also denied any past imaging of his back. 
For the patient's review of systems, he denied any chest pain, palpitations, shortness or 
breath, or a current cough. The patient was asked if there were any abnormalities in his urination 
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including weak stream, nocturia, or difficulty with urination – all which were denied. The patient 
also denied any trouble with constipation, diarrhea, blood in stools, or abdominal pain. 
Regarding his musculoskeletal, the patient denied any gait imbalance, weakness, catching, 
locking, or giving way of his bilateral lower extremities. No paralysis, weakness, dizziness, 
changes in vision, or numbness/tingling to bilateral lower extremities was endorsed; although the 
patient did admit to pain in the low back radiating to right thigh.  
Physical Exam and Treatment 
 The physical exam was conducted on musculoskeletal ability, as the correct diagnosis 
was missed. The shirt of the patient was not lifted, therefore his skin was not examined. In 
general, the patient was not in distress and responded to commands. His upper extremities which 
were exposed were appropriate in color, turgor, and did not present with lesions or rash. His 
head, ears, eyes, and throat showed: no matted lashes, masses, clear conjunctiva, normocephalic 
head, moist pink lips and mucosa, symmetrical eyes and ears. His neck was symmetrical without 
masses, and trachea midline. Respirations anterior and posterior were clear and unlabored. 
Cardiac rhythm auscultated for murmur, rub, gallops- all which were not present. S1 and S2 
present. The abdomen was soft and nontender with audible bowel tones in all four quadrants. 
Neurologically, the patient was alert and oriented to self, place, situation, and time. There were 
no fleeting of ideas and he was able to hold a conversation with clear speech. 
  The focused back exam revealed tenderness with vertebral palpation. The patient was 
able to follow commands for forward flexion, hyperextension, bilateral lateral flexion with pain 
on the right side, and bilateral rotation with grimacing when rotating to the right side. 
Extremities revealed no trauma or cyanosis. Gait seemed to have been effected by right sided 
RECURRENCE OF SHINGLES 6 
pain with slight limping, but patient was able to get up and down exam table. Leg raise test not 
done due to patient stating too much pain when laying on his back. Radial pulses 2+.  
 Skin exam revealed a classic vesicular rash on the right low back consistent with shingles. 
Recommended treatment for this would include: antiviral, tramadol, appropriate use of ongoing 
Tylenol at home to not exceed daily limit of 4,000mg. Antivirals discussed were acyclovir or 
valacyclovir, which would depend on patients most recent labs, specifically his kidney function; 
but currently without a history of any baseline labs and no formal diagnosis of kidney disease or 
injury. The patient would be appropriate for either antiviral. Acyclovir at 800mg five times a day 
for 7 days, by mouth; or valacyclovir at 1000 mg every 8 hrs for 7 days, by mouth (Albrecht, 
Hirsch, & Mitty, 2017). Preference for valacyclovir would be given as frequency of dose is less 
and possibly for missed dose decreased (Albrecht, et al., 2017). Follow up for healing 
progression or pain continuation would be encouraged.  
Education and Discussion 
 Education regarding transmission of disease would include: avoid contact with 
individuals who have not had chickenpox or without the varicella vaccine, especially pregnant 
women, premature babies, or any immunocompromised persons (CDC, 2016). The patient would 
also need to cover his rash and wash his hands frequently, and refrain from itching or scratching 
his rash as the fluid from the lesions can directly spread the virus (CDC, 2016). In addition to 
prescribed and OTC medications, the patient could try oatmeal baths, calamine lotion, or a wet 
compress to help soothe the skin (CDC, 2016). Of course, the shingles vaccine would need to be 
advised for future prevention unless the patient has had a severe reaction to neomycin or gelatin; 
patients who are immunocompromised, pregnant women, or anyone with a current acute illness 
with fever at 101.3 degrees Fahrenheit or higher (CDC, 2016). If the patient does not remember 
RECURRENCE OF SHINGLES 7 
receiving the vaccine or records cannot be found the patient is safe to get another dose, and even 
if the patient had shingles in the past they are appropriate for vaccination.  
 Because we did not have information on whether our patient was vaccinated in the past, nor did 
the patient recognize the signs and symptoms of the rash. This patient, in particular, would 
benefit from education in regards to possible recurrence, as the virus never leaves the body. If he 
does feel that he has exposed at-risk individuals prior to visiting the primary care office, he can 




 The exam of the 67-year-old Caucasian male, who presented with a chief complaint of 
back pain led to a visualization of a vesicular rash. The rash was located on his right lower back 
characterized as “pins and needles.” The process in which a diagnosis is made may be skewed by 
what we learn to be characteristic signs of one disease. The importance of processing differential 
diagnosis is to get down to an accurate conclusion. Ruling out possible outcomes assists in the 
critical thinking process. Naturally, after a diagnosis is made, the treatment and plan follow, but 
if the disease is one that may reoccur, healthcare practitioners should educate and understand 
preventative measures. The recurrence of varicella zoster virus (VZV) is a controversial topic 
within current literature. From this review, we uncover that misdiagnoses in the past have created 
a controversial topic over speculated rate of recurrence in VZV. We will explore the most 
common misdiagnosis discussed within literature, and best practice methods into how to 
differentiate a correct diagnosis. Further studies relating to recurrence bring up the importance of 
protecting individuals from recurrence. One way of doing this may be to further study the role 
vaccines play in HZ and what age is most appropriate for boosters. Finally, the current treatment 
method for HZ and the future science has in regards to new antiviral therapy will be discussed. 
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Often times during an assessment, healthcare practitioners may recognize characteristic 
rashes or symptoms that point towards a specific diagnosis. In our case, the visualized lesions 
follow the characteristic VZV presentation, following a dermatome within the basal layer of the 
skin (Kinchington, Guedon, & Hendricks, 2012). It is important to note there are also cases that 
do not present with any rash (Kinchington, et. al., 2012; Fox, Galetta, Mahalingam, Wellish, 
Forghani, & Gilden, 2001). Most of the controversy with recurrence is the differentiation 
between herpes simplex virus (HSV) and VZV. All three (HSV-1, HSV-2, VZV) viruses are 
acquired with a primary self-resolving infection of the skin or mucosa, which leads to latency 
and possible recurrence (Kinchington, et al., 2012). Not only are the viruses similar in 
presentation and latency but they share genes that encode similar functions on their host.  
Differentiating between HSV and VZV should be understood, as there is controversy of 
misdiagnoses of recurrent VZV. As advanced testing emerges, such as polymerase esterase chain 
reaction (PCR), practitioners can now better determine HSV versus VZV outbreaks. Studies in 
the past (not using PCR but viral culturing) found 25% of outbreaks diagnosed as VZV were, in 
fact, HSV (Burkhart, 2002). Approximately one-fourth of herpetic eruptions diagnosed as VZV 
are confirmed to truly be HSV cases (Pierson, 2017). As a rule in dermatology, repetitive 
herpetic outbreaks are HSV infections until proven to be VZV (Burkhart, 2002). Within the 
immunocompetent patient population, there have been confirmed misdiagnosed recurrent VZV 
cases, which also create controversy of the real rate of recurrence (Chien, Andy, & Olerud, 
2007). Sticking to the most up to date facts on differentiating one virus from the other will be 
critical in correct diagnosis, treatment, and prevention for our patients. Current laboratory 
diagnostics that can assist in differentiation include PCR, enzyme-linked immunosorbent assays, 
and immunofluorescence (Burkhart, 2002).  
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VZV is known to target the bodies immune system and establish a latency similar to 
HSV. The virus is transmitted through aerosol and inhalation. One difference is that VZV 
becomes dormant in multiple sensory neuronal nuclei, which gives the virus the ability to 
reoccur anywhere in the body (Kinchington, et al., 2012). While HSV lesions tend to affect one 
or few neurons and recur at the primary site of infection (Kinchington, et al., 2012). The area of 
the primary infection does not always foreshadow the recurrent location in HZ. Another variance 
between HSV and VZV is that recurrence rates increase with age whereas with HSV the 
recurrence rate drops with age (Kinchington, et al., 2012). Currently, the rate of recurrence of 
VZV and the mechanism behind how the virus maintains a latent state is unknown (Kinchington, 
et al.,2012). Due to the fact that VZV is much more reliant on host; current animal model 
mimicking viral recurrence is rare or nonexistent. Kinchington, et al. (2012) also state the 
extreme difficulty of reactivating human ganglia to study the recurrence of VZV. 
 Since we do know the recurrence rate correlates to immune system functioning, 
specifically the degradation of it, our older population will be at increased risk. HSV recurrence 
is triggered by both environmental and physiologic factors, VZV is not as closely linked to such 
triggers (Kinchington, et al., 2012). Our older individuals are at a higher risk for recurrence due 
to immune senescence. Although rash does not always present, 90% of patients with VZV suffer 
from pain which almost always involves neurological roots (Kinchington, et al., 2012). 
Pain is another characteristic that differentiates VZV from HSV. Because pain can be a 
debilitating complication from VZV, the issue of recurrence should be worrisome for current 
healthcare professionals. The pain occurs during the active disease and the possibility of chronic 
postherpetic neuralgia (PHN) is also well known. PHN is pain that persists for 3 or more months 
after the VZV lesions crust (Tseng, Lewin, Hales, Sy, Harpaz, Bialek, et al., 2015). Kinchington, 
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et al. (2012) state that HZ patients develop PHN at a rate of more than 30%. The Centers for 
Disease Control (2016) states approximately 13% or more of individuals over the age of 60 to be 
at risk for PHN. This pain can lead to depression, insomnia, and decreased activity to name a 
few. In regards to developing PHN Tseng, et al. (2015) found that vaccination prior to VZV 
decreased rates of PHN in women.  
Nakamura, et al  (2016) found that Japanese patients age 50-79 years old had less severe 
pain associated with recurrent VZV versus primary VZV infection. Individuals 80 years old or 
older did not experience this less severe recurrence. This might be the case as cell-mediated 
immunity in the recurrent individuals were stronger in the 50-79-year-old population (Nakamura, 
et al., 2016). Not only is recurrent pain noted to be less severe, but also the lesion development 
was less severe in crusting, erythema, vesicles, pustules, erosions, ulcerations, and fusion of 
vesicles (Nakamura, et al., 2016). Depending on the age when the patient develops their primary 
VZV infection, the immune response will be varied. This means if a patient experiences primary 
VZV infection later in life the weaker the immune booster response will be.  The implication of 
this information is that the older population is predisposed to a recurrence that is closer to their 
primary date of infection, along with similar pain and lesion to their primary experience. In this 
particular study, no difference was noted between genders or immunocompetent versus 
immunocompromised patients (Nakamura, et al., 2016).  
Studies have proved the efficacy of the HZ vaccine to be 51.3% effective in preventing 
HZ in adults at 60 years old or older, but the protection wearing off with time (Levin, Schmader, 
Lei, Williams-Diaz, Zerbe, et al., 2016). Levin, et al. (2016) has confirmed that giving the zoster 
vaccine at an earlier age (particularly at age 60 years old), prior to 70 years old or older produces 
an increase in the cell immunity response. Although the vaccine's cell-mediated immunity 
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persists for 10 years or more, a booster has shown to enhance the immunity for older populations 
(Levin, et al., 2016). The question now is when to give the booster, as the age and primary 
infection date vary, this all plays a role in the longevity of the immune system's reaction to the 
vaccine. Levin, et al (2016) suggests further studies in order to investigate appropriate booster 
interval for immunization against HZ.  
Currently, the Advisory Committee on Immunization Practices (ACIP) states that the 
zoster vaccine is most appropriate at the starting age of 60 years old. The United States Food and 
Drug Administration (FDA) has approved the vaccine for individuals 50 years old and older 
(CDC, 2016). There is no recommendation for a booster, but rather focusing on the appropriate 
age to administer the initial vaccine. The CDC (2016) states the efficacy of the zoster vaccine to 
be uncertain after the first 5 years.  Current vaccination recommendations state to administer the 
shingles vaccine at age 60 years old,  as this time is prime for highest risk of zoster and its 
complications.  
Tseng, et al (2012) have confirmed this in their study showing a slightly higher trend to 
decrease VZV recurrence in individuals less than 70 years old when vaccinated; but they also 
mention the low recurrence rate overall in immunocompetent individuals and also raise the issue 
of possible vaccine shortage. Jumaan, et al. (2005) state that the rise in varicella vaccine for 
children has not been the reason for increased zoster virus incidence in adults. Therefore, the 
trend for increased incidence in VZV is still unknown, though currently we know it has been 
increasing prior to varicella vaccine in the United States (CDC, 2016). 
In regards to current treatment, Albrecht et al. (2017) suggest antiviral therapy if onset 
has been 72 hours or less, in order to gain the maximum benefit. Patients that are 
immunocompromised should receive treatment no matter if the initial 72-hour onset has passed, 
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and for all individuals actively experiencing new lesions (even past 72-hour onset) are 
appropriate candidates for antiviral therapy (Albrecht, et al., 2017). The drug of choice depends 
on patients and their renal function, as acyclovir clears via the kidneys. The top choices for 
antiviral therapy are valacyclovir or famciclovir, as the doses are less frequent and the efficacy 
has been studied to be the same (Albrecht, et al. 2017). Additional therapies for symptoms 
related to pain include narcotics, NSAIDS, and/or Acetaminophen – depending on the pain 
rating. Bowsher (1997) studied the efficacy of using tricyclic antidepressants, particularly 
amitriptyline for treatment of neuritis or to prevent PHN, but without significant results as there 
were many limitations.  Other more effective methods of treating acute herpes zoster pain are 
oxycodone, although constipation is a well-known side effect; but gabapentin proved not to be 
any greater than placebo (Dworkin et al., 2009). Lastly, some providers may choose to use 
corticosteroids to improve acute symptoms, but with patients who present with uncomplicated 
herpes zoster, the course does not seem to prevent PHN (Han, Zhang, Chen, Zhou, & Zhu, 
2013).  
Although some practitioners may believe that recurrence of VZV is rare, there is current 
evidence to show otherwise. This itself should warrant healthcare practitioners to include 
recurrent VZV as a differential when assessing patients with classic signs and symptoms. Yawn, 
Wollan, Kurland, St Sauver, & Saddier (2011) have found that recurrence is as common as 
primary VZV infection; but rare within the first 12-18 months after the primary HZ episode 
(Tseng, 2012). Hales, et al. (2016) revealed recurrent VZV patients were not as likely to seek 
healthcare unless pain was severe; suggesting that prior studies using healthcare data may have 
underestimated the recurrent rate of VZV. Women are also more likely to suffer from VZV 
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recurrence (Hales, Harpaz, & Bialek, 2016.) Currently, the treatment for recurrent VZV is the 
same as the primary infection (Albrecht, et al., 2017).  
More studies are being conducted on the best antiviral treatment for herpes zoster. As 
viruses mutate and become resistant, newer drugs have been made. For example, valacyclovir 
which is approved for VZV treatment may be a better choice than the traditional acyclovir, a 
guanosine analog. This is the case because valacyclovir has an increased absorption and 
bioavailability (De, Hart, & Breuer, 2015). A newer drug has gone through phase 2 trial, called 
valacyclovir has been found to be noninferior to valacyclovir in treating herpes zoster (De, et. al., 
2015). For patients who have passed the 72-hour mark and now have encrusted lesions the 
benefits of antiviral are minimal (Albercht, et al., 2017). The individuals who benefit most from 
antiviral therapy are patients older than 50 years old who have a history of pain lasting longer 
with their zoster; but overall the antiviral’s are given to reduce severity of pain and increase the 
healing time of skin (Albrecht, et al., 2017). If secondary bacterial infections or complications in 
the eye occur then additional treatment therapy is to be added and antiviral therapy may be 
prolonged (Albercht, et al., 2017).  
Returning to our initial 67-year-old male patient, his case is uncomplicated VZV, 
presenting classically with dermatomal vesicular rash and acute neuritis, PCR is unlikely needed 
to confirm diagnosis, although further investigation into past history could be useful for 
documentation to determine likelihood of HSV or if this current case is recurrent. Since he also 
presented before the 72-hour window, the patient was a good candidate for an antiviral, 
preferably valacyclovir. For prevention of recurrence, we would want to educate on receiving 
vaccination and keeping up with health maintenance as he ages. Managing ongoing co-
morbidities will be key to keeping his immune system as healthy as possible. Healthcare 
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providers can additionally take time to educate patients if acute neuritis is felt (as it can precede 
the rash) they may make an appointment to be assessed for antiviral therapy early on, as to 






• The current and past rate of recurrent VZV is not known. There have been documented 
findings that have re-evaluated the research on VZV. These findings have concluded that 
previous studies have misdiagnosed VZV recurrence when the real infection was HSV. 
• The most recent research shows that most individuals with recurrence do not seek 
healthcare, unless their pain is severe.  
• So why should we care about herpes zoster recurrence? The answer is clear; as the older 
population continues to age and live longer the recurrence rate can also rise. Since we 
know that VZV rates increase with age and decline in immunity, our efforts to further 
prevent discomfort are valid, as pain can be debilitating. 
• Further studies are needed in order to determine if boosters may assist in prevention, and 
in what age group that would be most effective.  
• Overall, keeping recurrent VZV as a differential diagnosis in the back of our minds for 
patients most at risk: women, older age, immunocompromised patients; does not hurt our 
practice. If laboratory testing is needed, PCR is the most sensitive to distinguish between 
HSV. 
• Vaccinating individuals at or after the age of 60 years old is best practice and gives the 
best preventative coverage. 
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